Literature DB >> 27023083

Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis.

Kelly C Pearson1, Dean S Morrell1, Susan R Runge1, Puneet Jolly1.   

Abstract

Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous eruption that often is a reaction to medications, most commonly antibiotics. Clinically, AGEP closely mimics pustular psoriasis and also is similar to subcorneal pustular dermatosis and IgA pemphigus. For clinicians, it is important to differentiate AGEP from pustular psoriasis. Acute generalized exanthematous pustulosis will have an acute drug association. Few cases have been known to be caused by hydroxychloroquine (HCQ). Proper therapeutic management of AGEP includes withdrawal of the offending agent, and resolution typically occurs within 15 days. We report a case of AGEP after HCQ administration that did not follow the usual course of resolution after medication cessation. The patient continued to experience cutaneous eruptions that waxed and waned for 81 days. Hydroxychloroquine has a particularly long half-life and is a known cause of AGEP; therefore, it is possible that HCQ-induced AGEP may not follow the typical rapid recovery time.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27023083

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  8 in total

Review 1.  Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.

Authors:  Sergio Marin; Alba Martin Val; Maite Bosch Peligero; Cristina Rodríguez-Bernuz; Ariadna Pérez-Ricart; Laia Vilaró Jaques; Roger Paredes; Josep Roca; Carles Quiñones
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-21

Review 2.  Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues.

Authors:  Ashutosh M Shukla; Aparna Wagle Shukla
Journal:  Drugs Context       Date:  2019-11-25

3.  Ixekizumab for treatment of refractory acute generalized exanthematous pustulosis caused by hydroxychloroquine.

Authors:  Mohammad Munshi; Alexandra Junge; Karolina Gadaldi; Nikhil Yawalkar; Kristine Heidemeyer
Journal:  JAAD Case Rep       Date:  2020-05-17

4.  Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.

Authors:  Ivorie Coleman; Gabriel Ruiz; Sumir Brahmbhatt; Lindsay Ackerman
Journal:  J Med Case Rep       Date:  2020-11-03

5.  Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19.

Authors:  Tyler Enos; Haneol S Jeong; Travis Vandergriff; Heidi T Jacobe; Benjamin F Chong
Journal:  Dermatol Ther       Date:  2020-07-08       Impact factor: 3.858

Review 6.  Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.

Authors:  Antonio Martinez-Lopez; Carlos Cuenca-Barrales; Trinidad Montero-Vilchez; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  J Am Acad Dermatol       Date:  2020-08-07       Impact factor: 11.527

Review 7.  Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.

Authors:  Robert A Schwartz; Camila K Janniger
Journal:  Dermatol Ther       Date:  2020-04-16       Impact factor: 3.858

8.  Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital.

Authors:  Ali Nili; Ehsan Zarei; Azin Ghamari; Ali Salehi Farid; Soheil Tavakolpour; Maryam Daneshpazhooh; Hamidreza Mahmoudi
Journal:  Int Immunopharmacol       Date:  2020-10-19       Impact factor: 4.932

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.